EFFECT OF CLONAZEPAM ON CANNABIS WITHDRAWAL AND RELAPSE IN TREATMENT-SEEKING PATIENTS: COMBINED INPATIENT/OUTPATIENT STUDY
Clonazepam treatment for marijuana withdrawal to prevent relapse to marijuana use.
Sponsor: National Institute on Drug Abuse
Enrolling: Male and Female Patients
Study Length: 13 Weeks
Clinic Visits: 30
IRB Number: 7343
U.S. Govt. ID: NCT02913924
Contact: Daniel Brooks: 212-923-3031 / brooksd@nyspi.columbia.edu
Additional Study Information: The study will have half of the participants randomly assigned to receive placebo (a sugar pill) and the other half will receive clonazepam medication. For the first 5 nights participants will stay inpatient at the New York State Psychiatric Institute Inpatient unit. Then they will be discharged and continue to receive medication or placebo for the 12 weeks of the outpatient part of the study. For these outpatient 12 weeks they will come to the clinic 2 times per week.
This study is closed
Investigator
John Mariani, MD
Do You Qualify?
Are you currently using marijuana? Yes No
Have you used marijuana at least 20 days in the past month? Yes No
Are you between the ages of 18 and 65? Yes No
Can you stay inpatient for 5 nights? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Daniel Brooks
brooksd@nyspi.columbia.edu
212-923-3031